POSTERS AND PUBLICATIONS
At a Glance ...Quality Controls for Molecular Disease Testing
MMQCI’s multiplex quality controls are uniquely designed to process through the entire molecular testing process, including the extraction, amplification, and detection steps. Routine use provides labs with more confidence in test results by detecting immediate errors, and shifts or trends caused by changes in the environment and test system components. MMQCI products are 100% safe and nonhazardous, robust and stable.
Development of Synthetic Multiplexed External Controls for Monitoring the Performance of Qualitative Laboratory Nucleic Acid Testing Panels Used for Rapid Identification of Blood Culture Pathogens.
This poster was presented at the May 2019 Clinical Virology Symposium, Savannah GA, (USA). Maine Molecular Quality Controls Inc. (MMQCI) has developed unique, extractable multiplex control panels designed to monitor all pathogenic organisms and antibiotic resistance genes detected by GenMark’s ePlex® Blood Culture Identification (BCID) Gram-positive (GP), Gram-negative (GN), and Fungal Pathogen (FP) Panels.
Validation of a multiplexed synthetic control panel to monitor the performance of simultaneous detection of multiple respiratory viral, bacterial pathogens, and antimicrobial resistance genes in lower respiratory infections.
This poster was presented at the May 2019 Clinical Virology Symposium, Savannah GA, (USA).Maine Molecular Quality Controls Inc has validated and received FDA clearance for a stable, multiplexed synthetic control to be used as an external quality control to simultaneously monitor all 26 pathogens (or 27 pathogens, when using the Pneumonia Panel plus) and 7 antibiotic resistance markers detected by BioFire FilmArray Pneumonia and Pneumonia plus Panel.
Multiple Synthetic Reference Material for Monitoring the Analytical Performance of Highly Complex Variant Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) using Next Generation Sequencing.
This poster was presented at the November 2018, Association of Molecular Pathology Annual Meeting held in San Antonio, TX (USA). The poster details the development and performance of our new NGS CF Control Panel G211 v1.1, an updated version of NGS CF Control Panel G211, which includes additional sequences to optimize function for enhanced coverage and accurate detection of 188 variants present in the CFTR gene.
Development of synthetic secondary standards for BCR-ABL1 quantification on GeneXpert® BCR-ABL Monitor V2 and Xpert® BCR-ABL Ultra assays.
Presented at the November 2018, Association of Molecular Pathology Annual Meeting held in San Antonio, TX (USA), this poster reviews the development of Xpert BCR-ABL IS Panel C130 for use as a reference material to monitor the performance of the in vitro quantitative detection of the BCR-ABL1 translocation mRNA e13a2/b2a2 or e14a2/b3a2 transcripts and the ABL1 endogenous control mRNA transcript when analyzed using the GeneXpert® BCR-ABL V2 assay, or the Xpert® BCR-ABL Ultra assay on the Cepheid GeneXpert® Instrument Systems.